About Syndax

We are a late-stage biopharmaceutical company employing epigenetics – a novel way to control gene expression – to overcome the problem of resistance seen with current oncology treatments. We are focused on the development and commercialization of our lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.